BioSpace News Archive

Ninth GPCR-targeted drug candidate overall generated from Sosei Heptares’ StaR® technology/SBDD platform to enter clinical development

Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children’s Hospital and professor at Harvard Medical School, will assist on MINDCURE’s digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform

Synthace Ltd, the cloud-based software platform for automating biological R&D, announced the appointment of Guy Levy-Yurista as Chief Executive Officer and Board Member to guide Synthace through its next stage of growth.

Grifols, a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, announced it’s collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer’s disease will be applied to obtain data from clinical practice.

The International Myeloma Foundation said that research published this week in Blood Cancer Journal could lead to a paradigm shift in myeloma therapy towards screening for the precursor for the disease and treating early.

University owned research patents will expand Quercis’ antithrombotic and anti-inflammatory pipeline in a variety of indications including COVID-19 and neurological conditions

Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces the acquisition of Freehold Physical Therapy in Freehold, New Jersey.

Silence Therapeutics today announced positive topline data from the GEMINI phase 1 study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anemia conditions, thalassemia and myelodysplastic syndrome (MDS).

Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors.

FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders in almost a decade